** Shares of Mayne Pharma Group MYX.AX soar 13.3% to A$5.30, their highest level since December 3, 2024
** Stock heads for a fourth consecutive session of gains, among top gainers in the ASX All Ordinaries index .AORD
** Speciality pharmaceutical firm says it expects 1H25 underlying EBITDA between A$30 million ($18.76 million) and A$32 million, up to four-fold jump from last year's A$8 million
** Revenue forecast between A$210 million and A$215 million, up to 14% growth
** Co expects to see continued growth in 2H25
** More than 112,000 shares change hands, vs the 30-day average of about 95,000 shares
** MYX up 6.8% this year, including day's moves
($1 = 1.5995 Australian dollars)
(Reporting by Sameer Manekar in Bengaluru)
((Sameer.Manekar@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.